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Abstract  35 
Background. Necrotizing skin and soft tissue infections (NSTI) are rare but potentially life-36 
threatening and disabling infections that often require intensive care unit admission.  37 
Objectives. To review all aspects of care for a critically ill patient with NSTI.  38 
Sources. Literature search using Medline and Cochrane library, multidisciplinary panel of experts. 39 
Content. The initial presentation of a patient with NSTI can be misleading, as features of severe 40 
systemic toxicity can obscure sometimes less impressive skin findings. The infection can spread 41 
rapidly, and delayed surgery worsens prognosis, hence there is a limited role for additional imaging 42 
in the critically ill patient. Also, the utility of clinical scores is contested. Prompt surgery with 43 
aggressive debridement of necrotic tissue is required for source control and allows for 44 
microbiological sampling. Also, prompt administration of broad-spectrum, antimicrobial therapy is 45 
warranted, with the addition of clindamycin for its effect on toxin production, both in empirical 46 
therapy, and in targeted therapy for monomicrobial group A streptococcal and clostridial NSTI. The 47 
role of immunoglobulins and hyperbaric oxygen therapy remains controversial.  48 
Implications. Close collaboration between intensive care, surgery, microbiology and infectious 49 
diseases, and centralization of care is fundamental in the approach to the severely ill patient with 50 
NSTI. As many aspects of management of these rare infections are supported by low quality data 51 
only, multicentre trials are urgently needed.   52 
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Manuscript 53 
Introduction 54 
Necrotizing skin and soft tissue infections (NSTI) refer to infections of the skin, subcutaneous tissue 55 
and superficial fascia, that are characterised by the development of necrosis in these structures. 56 
The term NSTI covers a range of infections that can occur in different anatomical locations and 57 
develop after the integrity of the skin (or mucosa) has been breached. NSTI are rare, but 58 
destructive and potentially lethal infections and patients often require admission to an intensive 59 
care unit (ICU).  60 
 61 
NSTI are challenging because of a number of characteristics that distinguish them from other 62 
severe infections, including the ones reviewed in this issue of CMI. The diagnosis in the early phase 63 
of the disease is difficult as skin lesions may appear benign at first and hemodynamic instability can 64 
be absent. A high index of suspicion is required and diagnosis is often based on clinical clues that 65 
may trigger additional investigations, but their role is limited, notably in the most critically ill. NSTI 66 
can progress rapidly; the resulting tissue damage is often extensive, requiring surgical source 67 
control and reconstructive surgery in most patients and frequently leaving the patient with a 68 
permanent disability. 69 
 70 
The management of these severe cases should prioritize timely diagnosis and intervention, with a 71 
central role for surgery and appropriate antibiotic therapy. All of this should be executed in a short 72 
time frame, so this requires swift decision making, and preferably an experienced multidisciplinary 73 
team to treat the patient.  74 
 75 
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Previous reviews have focused on either specific aspects of therapy or care, e.g., surgery, antibiotic 76 
therapy [1, 2] or ancillary treatments such as hyperbaric oxygen [3–5] or immunoglobulins [6];  a 77 
particular anatomical location [7–10], a specific pathogen [11–13], or they took a very broad 78 
perspective covering non-necrotizing infections as well [14–16]. 79 
 80 
In this narrative review, we want to focus on all aspects of care for these patients in the ICU, 81 
through the eyes of a multidisciplinary panel reflecting the approach required in severe infections 82 
in the ICU. This overview is based on an extensive literature search focusing on information 83 
published in the last years. 84 
 85 
 86 
Methods 87 
A literature search was performed on PubMed and the Cochrane Library on December 2
nd
, 2018 88 
(see Figure 1 for PRISMA flow diagram). The following MeSH terms were used: “intensive care 89 
units”, “critical care”, “critical illness”, “fasciitis, necrotizing”, “Fournier gangrene”, “gas gangrene”, 90 
“soft tissue infections” and “skin diseases, infectious”.  In addition, the following free text words 91 
were used: “intensive care unit”, “necrotizing fasciitis”, “gas gangrene”, “soft tissue infection”, 92 
“skin infection”, “cellulitis”, “myositis” and “necrotizing”. We applied filters for publications from 93 
01/01/2004 onwards, written in English. Case reports were excluded, as were articles that did not 94 
involve critically ill patients with NSTI. We also searched the reference lists of relevant recent 95 
review articles [17, 18].  96 
 97 
 98 
Epidemiology 99 
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NSTI are rare, with a population incidence of 4 per 100 000 per year [19–23], and account for a 100 
small proportion of ICU admissions, estimated at 0.2% in the UK [24] or 1.2% of all critically ill 101 
patients admitted with sepsis in the Netherlands [25]. However, because of the severity of illness, 102 
underlying comorbidities and intensity of postoperative wound care, ICU admission is frequently 103 
required [22, 23, 26–31]. A quarter to half of patients with NSTI develop septic shock [23, 29, 30, 104 
32] and/or require mechanical ventilation [26, 29, 33] and a third exhibit acute kidney injury [30, 105 
33, 34]. Organ failures tend to worsen in the first 24 hours of admission [34]. The duration of ICU 106 
stay typically ranges from 5 to 12 days [25, 29, 31, 32, 35–38].  107 
 108 
The average age of NSTI patients is 50-60 years old [23, 26, 29, 31–35, 39–41], with a slight male 109 
predominance [22, 23, 26, 27, 29–37, 39–42]. Necrotizing fasciitis of the extremities is the most 110 
frequent clinical presentation [23, 27, 29, 31–34, 36, 37, 39, 41, 42], followed by perineal NSTI also 111 
known as Fournier’s gangrene [26, 31–36, 41, 42] (Table 1). Involvement of the trunk or head and 112 
neck region are less frequent [26, 27, 31, 33, 36, 39, 42]. Four to 12 % of NSTI patients have a 113 
recurrent NSTI [26, 27, 31, 33]. Comorbidities associated with NSTI include diabetes mellitus in 22-114 
59% [22, 23, 26, 27, 29–31, 33, 35–37, 39, 42] and obesity in 17-31% [26, 30, 35–37, 41, 42]. Other 115 
risk factors include cardiovascular (9-45%) or peripheral vascular disease (3-19%) [22, 23, 26, 30, 31, 116 
33, 36, 39, 41, 42], intravenous drug use (2-80%) [27, 33, 36, 39], immunosuppression (4-30%) [23, 117 
25, 30, 35, 36, 42] and chronic alcohol abuse (6-27%) [30, 33] (Table 1). Of note, up to a fourth of 118 
NSTI patients have no obvious predisposing factor [30, 36, 37, 39]. In 10-38% of NSTI patients, a 119 
local trauma is noted as the portal of entry; this can range from a minor skin abrasion or insect bite, 120 
to an operative injury or a blunt trauma. NSTI can also develop on the background of a chronic 121 
wound or dermatosis [29–31, 33, 36, 39]. Use of non-steroidal anti-inflammatory drugs (NSAIDs) is 122 
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regularly noted in the weeks prior to admission, potentially masking the clinical signs and 123 
symptoms of a developing NSTI; however, a causal relationship is not established [23, 30, 42, 43]. 124 
 125 
 126 
 127 
Table 1. Clinical pictures of NSTI  (based on [17, 19, 26, 27, 29–50])  128 
Location of NSTI Relative 
frequency* 
Portal of entry Main risk factors 
Limb (lower > upper) 
 
70% 
 
Trauma 
Chronic leg ulcer 
Burns 
Insect bites 
IV drug use 
Blunt trauma 
Varicella 
 
Age > 60 years 
Male gender 
Immunosuppression 
Diabetes 
Obesity 
Chronic lower limb ischemia 
 
Perineal/genital 
(Fournier’s gangrene) 
 
15% 
 
Cutaneous 
Digestive 
Urinary/genital 
 
Diabetes 
Obesity 
 
Cervical 
 
<5% 
 
Tonsillar phlegmon 
Dental abscess 
Gland infection 
 
Glucocorticoids 
 
Thoraco-abdominal 
 
<5% 
 
Post-operative 
 
Diabetes 
Obesity 
 
Orbital <5%  Diabetes 
Trauma 
* 
The reported figures are estimates and may vary depending on local patient recruitment and case 129 
mix. 130 
 131 
Patients with NSTI have considerable long-term functional disabilities. In one report, only half of 132 
them were able to return directly home while the others needed further hospitalization or transfer 133 
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to an inpatient rehabilitation facility [26]. Importantly, ~10-20% of patients with limb NSTI will 134 
eventually require amputation [23, 27, 30, 33, 34, 36, 38, 42, 45].  135 
 136 
About 20-30% of patients with NSTI die during their hospital stay [22, 24, 33, 36, 39, 40], though 137 
mortality may be lower depending on case mix [33, 34]. Risk factors for mortality are disease 138 
severity, reflected by severity of illness scores such as the APACHE II [33, 35, 41, 45], or hypotension 139 
and/or vasopressor need [23, 29, 36, 39]. Per unit increase in the APACHE II score, studies found a 140 
16-18% increased odds of death [23, 29]. If a patient is hypotensive on admission, the mortality 141 
doubles [48]; while the odds ratio for mortality is 28.4 (95% CI 1.35–77.8) if vasopressors are 142 
required on admission to ICU [29]. Bacteraemia upon admission was also reported to be associated 143 
with mortality [29]. Other non-modifiable prognostic factors include age [22, 26, 29, 32, 36, 37, 40, 144 
47, 50] and female gender  [22, 48]. Diabetes is not consistently associated with mortality risk [21, 145 
23, 32]. Other comorbidities such as cardiac [48], peripheral vascular [36] and chronic kidney [36] or 146 
liver disease [44] worsen prognosis. Potentially modifiable risk factors associated with NSTI 147 
mortality include the delay to surgical intervention [26, 46, 49], as well as the experience of the 148 
surgeon [33] and the case volume of the hospital [22] .  149 
 150 
 151 
Microbiology 152 
Current knowledge about pathogens involved in NSTI is essentially based on data from 153 
retrospective cohort studies that present data based on culture dependent detection of microbes 154 
from blood and sterile site tissue cultures [30, 47, 48, 50–52]. Identification of etiological agents 155 
may assist infection control measures and antimicrobial therapy decision making and may offer 156 
prognostic information. Drug susceptibility tests are useful in fine-tuning of antimicrobial therapy 157 
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but, using the current technologies available in routine in bacteriology lab, they are available after 158 
at least 2 or 3 days which is detrimental based on the severity of NSTI in ICU patients [47, 51, 52]. 159 
NSTIs are often categorized according to causative organisms [17, 53]. Type I infections are 160 
polymicrobial with anaerobic, aerobic and facultative anaerobic bacteria acting synergistically. 161 
Differently, type II infections are monomicrobial. Streptococcus pyogenes (group A streptococcus; 162 
GAS) is the most frequent pathogen, followed by other beta-haemolytic streptococci such as 163 
Streptococcus dysgalactiae that is emerging [54–57].  In case of NSTI caused by GAS, close to 50% of 164 
the cases were found to be associated with streptococcal toxic shock syndrome (STSS) [58, 59]. In 165 
fact, due to the frequent association, soft tissue necrosis, including necrotizing fasciitis, myositis, or 166 
gangrene, is included in the consensus definition of STSS [60].  Staphylococcus aureus including 167 
methicillin-resistant S. aureus (MRSA), Clostridium species, Vibrio vulnicifus and other gram-168 
negative bacilli are uncommon causes of type II infection [61–63]. A myriad of bacterial species 169 
including MDR gram-negatives may be cultured from NSTI, even more so in immunocompromised 170 
patients [64, 65]. 171 
 172 
NSTIs can also be categorized according to the anatomical location of the infection (Table 1), and 173 
the microbiology differs according to the implicated site.   174 
Anogenital and abdominal infections are secondary to gastrointestinal or genitourinary infections 175 
that eventually spread along tissue planes. Essentially these are type I infections and pathogens are 176 
similar to those of intraabdominal and genitourinary infections [53]. Multi-drug resistant (MDR) 177 
organisms, e.g., ESBL-producing Escherichia coli or Klebsiella spp., or MRSA, are reportedly 178 
emerging in different parts of the world [61, 66, 67]. In Fournier’s gangrene the importance of 179 
anaerobic bacteria may have been underestimated [68]. 180 
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Among deep neck space infections type I NSTI predominate [69]. The most important pathogens 181 
are viridans streptococci, staphylococci and gram-negative anaerobes such as Bacteroides fragilis, 182 
Prevotella, Fusobacterium and Peptostreptococci [69–71]. Clindamycin resistance is frequent 183 
among anaerobic bacteria [71], reaching 20 to 40% in the Bacteroides fragilis group in Europe [72]. 184 
Upper respiratory tract pathogens as Streptococcus pyogenes and Haemophilus influenzae may be 185 
encountered, whereas MDR pathogens are detected in a few cases [71]. There is risk of 186 
intrathoracic, prevertebral or intracranial spread. 187 
In most cases NSTI of the limbs lower extremity infections predominate (Table 1).  Type I infections 188 
are possibly more frequent [17], particularly in the lower limbs, whereas in type II infections GAS is 189 
the dominant cause [21, 30, 48, 73]. Even if GAS is isolated, in 30% of cases other micro-organisms 190 
are also found [74]. The risk of polymicrobial type I infections is increased in diabetes mellitus [75], 191 
including risk for infections with MDR organisms.  Risk factors for MRSA involvement include 192 
intravenous drug abuse, diabetes mellitus and chronic liver disease [75, 76].  In subtropical areas 193 
Vibrio vulnificus is a pathogen causing NSTI after exposure to seawater or consumption of raw sea 194 
food. Major host risk factors are chronic liver disease and immunosuppression [61, 63, 77]. 195 
 196 
 197 
Diagnosis 198 
Clinical picture 199 
Early recognition of NSTI is a key step of patient management. Because cutaneous manifestations 200 
may be initially absent, the infection was shown to be misdiagnosed at first presentation in 71% of 201 
cases in a systematic review including 1463 patients [78], resulting in delayed diagnosis, antibiotic 202 
administration and surgery referral. Patients with NSTI typically present with signs of severe 203 
infection, including malaise, myalgia, diarrhoea and anorexia, which sometimes precede skin 204 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 11
lesions [17] (Table 2). Upon hospital admission, and as compared to patients having non-necrotizing 205 
skin and soft tissue infections (e.g., cellulitis), patients with NSTI are more likely to have sepsis or 206 
septic shock [79]. The clinical presentation of NSTI varies depending on the location (Table 1) and 207 
the course (Table 2) of the infection. Clinical findings were reviewed by Goh et al. after a systematic 208 
literature search that identified swelling (present in 81% of NSTI cases), pain/tenderness (79%), 209 
erythema (71%), warmth (44%), bullae (26%), skin necrosis (24%) (Figure 2), and crepitus (20%) as 210 
the most frequently encountered signs [78]. Fever was present in 40% of cases and hypotension in 211 
21%, although the frequency of associated organ failures varies widely between studies, depending 212 
on the case mix, rising to 90% when only patients admitted to the ICU were included [25]. Because 213 
none of the previously mentioned signs provided a sufficient sensitivity when considered 214 
separately, approaches combining several clinical findings have been proposed and achieved better 215 
diagnostic yields than did each individual finding [80]. In atypical cases, involvement of 216 
dermatologists can aid in the differential diagnosis of NSTI from rare mimics such as pyoderma 217 
gangrenosum [81].  218 
 219 
Table 2. Signs and symptoms of NSTI, according to the course of the disease. 220 
Early  Late Very late 
Fever Purple discoloration  Frank necrosis 
Pain Haemorrhagic bullae Dishwasher pus 
Erythema/warmth Crepitus Hypoesthesia 
Tenderness Hypotension  
Induration Organ failures  
 221 
 222 
Laboratory tests 223 
The Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score has been proposed as a 224 
diagnostic tool for distinguishing NSTI from other non-necrotizing skin and soft tissue infections, 225 
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based on the following laboratory tests: C-reactive protein, white blood cell count, haemoglobin, 226 
and serum sodium, creatinine and glucose levels. A score ≥6 was associated with a positive 227 
predictive value of 57 to 92% and a negative predictive value of 86 to 96% [82, 83] and associated 228 
with worse hospital outcomes [84]. External validity seems to be problematic however; Fernando et 229 
al. found that the score had poor sensitivity and concluded that it should not be used to rule out 230 
NSTI [85]. Due to its limitations, the LRINEC score has not been widely implemented. Other 231 
biomarkers may be elevated in patients with NSTI, including serum procalcitonin, creatine 232 
phosphokinase and lactate, but none of these have been shown to provide robust diagnostic yields 233 
in NSTI [86–88].  234 
 235 
Imaging 236 
For limb NSTI, standard x-rays show gas in the tissues in about 10-25% of cases and hence 237 
contribute little to the diagnosis [78, 89]. Computed tomography scans will most frequently show 238 
soft tissue swelling, which will not help discriminating between necrotizing and non-necrotizing 239 
cases. Magnetic resonance imaging (MRI) is the most effective method for diagnosing NSTI, 240 
showing thickening of the deep fasciae, with high signal on T2 images and contrast-enhanced T1 241 
images [90]. Importantly, MRI should not be performed in patients with septic shock in order not to 242 
delay surgery. Unlike patients having limb NSTI, those with cervical, thoraco-abdominal and 243 
perineal NSTI (Figure 3) may require a computed tomography scan to explore the portal of entry of 244 
the infection (Table 1) together with its extension [91, 92]. 245 
 246 
When the clinical suspicion of NSTI is high and/or when patients present with signs of sepsis/septic 247 
shock, prompt surgical exploration is warranted in order to confirm the diagnosis of NSTI, assess 248 
the need for debridement/amputation and obtain tissue specimens for microbiological analyses. 249 
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Direct examination and Gram staining can aid in diagnosis and antimicrobial decision making [93]. 250 
Postoperatively, patients with septic shock should be admitted to a critical care area. A proposed 251 
algorithm for the management of patients with suspected NSTI is given in Figure 4. 252 
 253 
Patient transfer 254 
Given the incidence of NSTI many physicians and surgeons may only rarely encounter NSTI. 255 
Experience in diagnosing and treating patients (particularly the surgical debridement) may 256 
therefore be limited and a transfer to a specialized center may be considered. In a study from 257 
France [22], the volume of patients treated was linked to improved outcomes. The decision to 258 
transfer a patient to a specialized center should be based on the experience and availability of a 259 
surgeon, the extent and severity of the skin lesions as well as the delay that would be incurred by 260 
the transfer [94]. In many instances, the first debridement is done in the admitting hospital, and the 261 
patient is transferred to a specialized center afterwards. 262 
 263 
Surgery 264 
Surgery plays a crucial role in NSTI management, both in diagnosis and treatment. Obtaining a 265 
frozen section biopsy in unproven NSTI has been proposed in earlier publications but has been 266 
abandoned meanwhile due to low accuracy [15, 17]. Therefore, in uncertain cases, early surgical 267 
exploration in the operating theatre is recommended in recent guidelines and reviews in order to 268 
prevent a delay in the diagnosis and treatment of NSTI [17]. A deep incision provides crucial 269 
information about the local tissue conditions: a vivid and unchanged fascia excludes a NSTI. Typical 270 
intraoperative finding in progressive NSTI are colliquative necrosis of the fascia and the 271 
subcutaneous layer with muddy, dishwater-like fluid [17, 26, 46, 78] (Figure 5). Moreover, surgical 272 
exploration offers the opportunity to obtain samples for culture and Gram staining.  273 
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 274 
Once the diagnosis of NSTI has been established, initial aggressive debridement of all infected 275 
necrotic tissue is indicated (Figures 2 and 3); in critically ill patients, a relook within 24 h is 276 
recommended to ensure the adequacy of source control [14]. A major amputation is rarely 277 
necessary in NSTI, except for patients suffering from clostridial myonecrosis [52].  278 
 279 
Several studies have addressed the timing of surgery in NSTI after admission to the hospital. Many 280 
studies are confounded by the fact that the time of admission does not correlate with the 281 
beginning of symptoms [95]. Nevertheless, a strong correlation between the timing of surgery and 282 
mortality was found. Patients who underwent surgery within 6-12 hours after admission had 283 
significant lower mortality rates than those who did not [46, 96, 97]. The optimal timeframe for 284 
intervention has not been established and different studies use different cut-offs. In patients with 285 
septic shock Boyer et al. found that time from diagnosis to surgical treatment of more than 14 h in 286 
patients was independently associated with hospital mortality (adjusted odds ratio 34.5, 95% CI 287 
2.05–572, p= 0.007) [96]. 288 
 289 
After debridement and once the wound is stable, the subsequent use of negative pressure therapy 290 
allows reduction of wound surface, extraction of wound exudate and cell detritus as well as 291 
induction of granulation [98]. Moreover, it eases wound management and increases patient 292 
comfort in the ICU. In Fournier‘s gangrene, a temporary diverting colostomy is helpful to reduce 293 
faecal contamination and control infection of large perianal wounds [99]. Adequate wound 294 
conditioning in NSTI is the prerequisite for secondary wound closure with plastic reconstructive 295 
techniques [100]. 296 
 297 
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Throughout the treatment, a close cooperation between surgeons and intensivists is essential in 298 
order to achieve surgical source control as early as possible in the early stage, and to facilitate 299 
reconstructive surgery later [16, 17]. 300 
 301 
 302 
Antibiotics 303 
There are no randomized clinical trials on empirical antimicrobial therapy in NSTI available, and 304 
data on optimal antibiotic treatment in NSTI are scarce [18]. Contemporary guidelines and 305 
recommendations offer pragmatic approaches as they are based on observational studies, 306 
experience in treatment of less severe infections, as well as experimental data.  Antimicrobial 307 
therapy in NSTI aims to achieve the following goals: 1. adequate activity against gram-positive 308 
pathogens and Enterobacteriaceae or other gram-negative microbes carrying risk for multidrug 309 
resistance (MDR); 2. reduced toxin production in infections with Streptococcus pyogenes or 310 
Clostridium perfringens; and 3. anaerobic coverage necessary in all polymicrobial infections [15].   311 
 312 
Clinical diversity may be huge in NSTI, but sepsis and septic shock are frequent. It is therefore 313 
particularly important to initiate broad-spectrum, bactericidal antimicrobial therapy without any 314 
delay upon diagnosis [14, 15]. Given the severity of illness and the lack of criteria that allow to 315 
discriminate mixed and GAS infection rapidly, a broad-spectrum antibiotic regimen should be 316 
selected, such as piperacillin-tazobactam, a carbapenem or a 3
rd
 generation cephalosporin 317 
combined with metronidazole, always with the addition of clindamycin to limit potential toxin 318 
production. Combination therapy using clindamycin is also recommended in the directed antibiotic 319 
therapy for monomicrobial gram-positive infection with GAS or Clostridium species [15]. Depending 320 
on local epidemiology, extended coverage for MDR pathogens may be required.  321 
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 322 
When aetiology is identified and susceptibility tested, therapy can be adjusted. Type II infection 323 
caused by GAS is treated with penicillin plus clindamycin [15]. GAS is unequivocally sensitive to 324 
benzyl penicillin, but only clindamycin reliably maintains efficacy in infections with large amounts of 325 
bacteria in stationary growth phase [101, 102], In addition, clindamycin diminishes streptococcal 326 
toxin production [103], an effect that was also demonstrated in an in vivo GAS NSTI murine model 327 
and proposed to contribute to less severe tissue pathology noted in clindamycin treated mice [104]. 328 
In two prospective observational studies of invasive GAS infections, including STSS and NSTI cases, 329 
clindamycin was found to be associated with a significantly improved survival [104–106]. Treatment 330 
options in less frequent aetiologies of monomicrobial NSTI are presented in Table 3. 331 
 332 
Duration of therapy is not well defined, but typically it is continued until operative debridement has 333 
been completed and the patient is recovering, usually lasting around 7-10 days in total.   334 
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Table 3. Directed antibiotic therapy of causes of NSTI. 335 
Bacteria isolated Antimicrobial agents Adult recommended dosage 
Polymicrobial 
(Streptococci,  
S. aureus, E. coli, 
Bacteroides spp.) 
Piperacillin/Tazobactam 
Or Meropenem 
Or Ceftriaxone + 
Metronidazole 
Or Cefotaxime + Metronidazole 
All with Clindamycin 
4,5g every 6h 
1-2g every 8h 
2g once daily + 0.5g every 8h 
 
1-2g every 6-8h+ 0.5g every 8h 
600-900mg every 6-8 h 
Monomicrobial  
group A Streptococcus  
(S. pyogenes) 
Penicillin G  
Or Ampicillin 
All with Clindamycin 
2-4 10
6
 units every 4-6h  
1-2g every 4-6h 
600-900mg every 8h 
Clostridium spp. Penicillin G  
Or Ampicillin 
All with Clindamycin 
2-4 10
6
 units every 4-6h  
1-2g every 4-6h 
600-900mg every 8h 
Aeromonas 
hydrophila 
Doxycycline 
Plus Ciprofloxacin 
Or Ceftriaxone 
100mg every 12h 
500mg every 12h 
1-2g once daily 
Vibrio vulnificus Doxycycline 
Plus Cefotaxim 
Or Ceftriaxone 
100mg every 12h 
1-2g every 8h 
1-2g once daily 
MRSA Linezolid 
Or Clindamycin (if susceptible) 
Or Vancomycin 
600mg every 12h 
600-900mg every 8h 
1g every 12h, trough level 
adjustment (15-25 mcg/ml)  
or 20-25mg/kg bolus followed 
by 25-35mg/kg/24h in 
continuous infusion 
ESBL-producing 
Enterobacterales  
(E. coli,  
K. pneumoniae) 
Meropenem 
Tigecyclin* 
1-2g every 8h 
50-100 mg every 12h 
Adapted from the 2014 Infectious Diseases Society of America guidelines (76). Antibiotic doses are 336 
for intravenous administration. ESBL = extended spectrum beta-lactamase. * Tigecyclin should not 337 
be used as monotherapy.   338 
 339 
Intravenous immunoglobulins 340 
Polyspecific intravenous immunoglobulin (IVIG) has been proposed as adjunctive therapy in severe 341 
infectious diseases because of its immunomodulatory functions and ability to opsonize bacteria and 342 
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neutralize bacterial toxins. The clinical value of IVIG in sepsis and NSTI remains to be demonstrated 343 
[107–109]. A recent meta-analysis of IVIG treatment of clindamycin-treated GAS toxic shock 344 
syndrome demonstrated a significant survival benefit [110]. The pooled data included 70 IVIG-345 
treated and 95 non-treated STSS patients. IVIG-treatment was associated with a significant 346 
reduction in mortality from 33.7% to 15.7 %.  The INSTINCT randomized trial of IVIG in NSTI of all 347 
etiologies observed no apparent effect of IVIG on self-reported physical functioning and mortality 348 
[109]. Further studies are needed to evaluate if there is any value of adjunct IVIG in NSTI subgroups, 349 
particularly NSTI caused by GAS.  350 
 351 
Hyperbaric oxygen therapy 352 
Hyperbaric oxygen therapy (HBOT) has been proposed as an adjunctive therapy for patients with 353 
NSTI. HBOT increases tissue oxygen tension in infected necrotic wounds and might potentiate 354 
antibiotic efficacy [111]. As a matter of fact, in an international survey on NSTI management, one 355 
third of responding intensivists considered that HBOT was a reason for patient referral to another 356 
centre [112]. Observational studies have reported conflicting results [73, 113]; Devaney et al. 357 
recently reported on a cohort of 344 patients with NSTI, 275 of whom received HBOT, which was a 358 
protective factor for hospital mortality in multivariable logistic regression analysis [73]. However, a 359 
Cochrane review that aimed at assessing the evidence concerning the use of HBOT as an adjunctive 360 
treatment for patients with NSTI failed to identify any trial meeting the inclusion criteria and could 361 
thus not support or refute its effectiveness [3]. The latest guidelines of the Infectious Disease 362 
Society of America on NSTI management did not recommend HBOT due to the lack of evidence and 363 
because of the risk of delaying resuscitation and surgical debridement [15]. 364 
 365 
Research perspectives 366 
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Many aspects of the management are supported by clinical data with low to very low quality only. 367 
High quality research is urgently needed in a number of areas (Table 4). Given the incidence of 368 
NSTI, international collaborative research is the only way to improve the care of these patients. On 369 
this note, a multicentre prospective observational study on NSTI (NCT01790698) [114], including 370 
both documentation of clinical and treatment variables as well as biobank collection was recently 371 
completed, and results are highly anticipated. 372 
 373 
Table 4. Research agenda on severe NSTI. 374 
Domain Research question/aim 
Pathophysiology How does the pathophysiology differ depending on causative 
pathogen and host susceptibility?  
Define pathogenic mechanisms and/or host responses that can be 
used for patient stratification and tailored therapy in NSTI 
Diagnosis What biomarkers can help in the diagnosis? 
Define endotypes that would allow for studying precision 
medicine strategies 
What is the role of rapid diagnostic techniques? 
Treatment Is there a role for IVIG in GAS NSTI? 
What is the effect of HBOT? 
Is combination therapy with clindamycin superior to 
monotherapy? 
Is aggressive surgery superior to conservative surgery? 
What is the appropriate duration of antibiotic therapy? 
Is there a benefit of negative pressure therapy? 
Organizational Do we need to centralize care for patients with NSTI? 
Outcomes What is the health-related quality of life after NSTI?   
 375 
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The pathophysiology of NSTI is incompletely understood, e.g., the role of the innate immune 376 
response to locally control these infections or on the other hand, mediate tissue pathology. Basic 377 
research in this field may help to find new targets for diagnostics and intervention, as well as 378 
provide critical insight to support patient stratification and personalized medicine in NSTI; GAS is an 379 
important pathogen and deserves particular attention. 380 
 381 
Given the low number of patients with NSTI, organizational aspects of care such as concentrating 382 
the care for these patients in a limited number of experienced hospitals seems logical but has been 383 
investigated incompletely. 384 
 385 
Even in the best circumstances delayed diagnosis is common and better tools such as biomarkers to 386 
diagnose and assess the risk of poor outcomes are a priority. Rapid diagnostic tools are under 387 
development and their role in NSTI could be very important. Molecular diagnostics represent 388 
important supplements, as they can detect relevant culture negative organisms [115, 116] and 389 
possibly shorten time to identification. There is a role for diagnostic microbiology [117] in 390 
development of novel therapies in NSTI. 391 
 392 
While the role of early antibiotics and surgery is obvious, the role of IVIG, HBOT and clindamycin 393 
remains unclear. As for the surgical procedure itself, both the timing and extent of initial 394 
debridement require further study. Optimal duration of therapy is another area of uncertainty. 395 
Non-antibiotic therapies - e.g., targeting bacterial virulence factors - could offer new treatment 396 
opportunities. 397 
The aftermath of NSTI should not be underestimated and continued high level care is important. 398 
Better-quality analysis of the impact of new strategies in reconstructive surgery such as negative 399 
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pressure therapy and optimized aftercare including psychological support and rehabilitation are 400 
also mandatory. 401 
 402 
 403 
Conclusion 404 
NSTI are life-threatening and disabling infections that remain a diagnostic and therapeutic 405 
challenge for clinicians. A multidisciplinary management involving not only intensivists, surgeons, 406 
microbiologists, infectious disease specialists, but also ICU nurses and physiotherapists is 407 
warranted. Early recognition of NSTI is a crucial step that should trigger the initiation of broad-408 
spectrum antibiotics and aggressive surgical debridement. A major collaborative effort is required 409 
to design pragmatic studies aiming at assessing treatment strategies using patient-centred 410 
outcomes. 411 
 412 
  413 
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Figure captions 414 
Figure 1. PRISMA flow diagram of literature search. 415 
Reasons for exclusion of articles are given. “Not NSTI” indicates articles not involving patients with 416 
necrotizing skin and soft tissue infections; (*) “other” reasons for exclusion of screened titles were 417 
non-clinical research (n=7), palliative care setting (n=1), medicolegal focus (n=1), conference 418 
abstracts (n=3); (**) “other” reasons for exclusion of screened full text articles were non-clinical 419 
research (n=1), therapy coding (n=1) and mechanistic research about HBOT (n=1). 420 
 421 
Figure 2. Clinical presentation before (left panels) and after (right panels) debridement in patients 422 
with lower limb NSTIs.  423 
A) A 56-year-old male with right foot Streptococcus pyogenes (group A streptococcus; GAS) NSTI; 424 
the picture shows leg and foot swelling with skin necrosis anterior to the external malleolus and 425 
large bullae; an extensive debridement was performed; B) A 25-year-old female with bifocal GAS 426 
NSTI; the left foot is swollen and has a lilaceous appearance, and there is a concomitant 427 
involvement of the right internal malleolus; C) Type I NSTI (tissue specimen grew Staphylococcus 428 
aureus and Citrobacter koseri) of the right foot in a 54-year-old male; the picture typically depicts 429 
swelling, erythema and skin necrosis. 430 
 431 
Figure 3. Clinical presentation of a patient with Fournier’s gangrene in a 74-year-old male with 432 
diabetes and paraplegia.  433 
 A) A picture taken upon hospital admission shows a stage IV sacral pressure ulcer together with 434 
scrotal skin necrosis; B) Transversal computed tomography scan slice depicting gas in the soft tissue 435 
and a collection between the sacral area and the scrotum; C) Post-operative aspect after drainage 436 
and right orchidectomy. 437 
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Figure 4. Algorithm for the approach to a patient with suspected NSTI. 438 
 439 
Figure 5. Clinical findings during surgery in a 65-year-old female with posttraumatic necrotizing 440 
fasciitis. A) After primary incision. Note the typical landscape-like necrotic areas of the skin and soft 441 
tissue; B) After radical debridement. All necrotic tissue has been removed, the muscle tissue is vivid 442 
and not affected. 443 
 444 
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MULTIDISCIPLINARY MANAGEMENT (Surgeon/Intensivist/Anesthesiologist)
CONSIDER ICU MANAGEMENT IF ORGAN FAILURES
CONSIDER SURGICAL MANAGEMENT AS SOON AS POSSIBLE
EMERGENCY SURGERY PERFORMED if
Severe sepsis/septic shock
Overt local signs of NSTI
• CONTINUE ANTIBIOTICS
• IMAGING (e.g. MRI) 
• DERMATOLOGY CONSULTATION
POST-OPERATIVE 
ASSESSMENT
DAILY MULTIDISCIPLINARY 
ASSESSMENT
• Consider second look surgery
• Assess need for supplemental debridement
• Adjust antibiotics based on microbiology
• Plan wound care/Analgesia/Check tetanus vaccination status
• Consider intravenous immunoglobulins if GAS
DAILY SURGICAL EVALUATION
NO EMERGENCY SURGERY PERFORMED if
No organ failure
Low clinical suspicion of NSTI
SUSPICION OF NSTI
Obtain microbiological samples (blood and skin cultures)
Initiate broad-spectrum antibiotic treatment
